Literature DB >> 33707701

RAGE ligands stimulate angiotensin II type I receptor (AT1) via RAGE/AT1 complex on the cell membrane.

Serina Yokoyama1, Tatsuo Kawai2, Koichi Yamamoto3, Huang Yibin1, Hiroko Yamamoto1, Akemi Kakino4, Hikari Takeshita1, Yoichi Nozato1, Taku Fujimoto1, Kazuhiro Hongyo1, Toshimasa Takahashi1, Futoshi Nakagami1, Hiroshi Akasaka1, Yoichi Takami1, Yasushi Takeya1, Ken Sugimoto1, Tatsuya Sawamura4, Hiromi Rakugi1.   

Abstract

The receptor for advanced glycation end-products (RAGE) and the G protein-coupled angiotensin II (AngII) type I receptor (AT1) play a central role in cardiovascular diseases. It was recently reported that RAGE modifies AngII-mediated AT1 activation via the membrane oligomeric complex of the two receptors. In this study, we investigated the presence of the different directional crosstalk in this phenomenon, that is, the RAGE/AT1 complex plays a role in the signal transduction pathway of RAGE ligands. We generated Chinese hamster ovary (CHO) cells stably expressing RAGE and AT1, mutated AT1, or AT2 receptor. The activation of two types of G protein α-subunit, Gq and Gi, was estimated through the accumulation of inositol monophosphate and the inhibition of forskolin-induced cAMP production, respectively. Rat kidney epithelial cells were used to assess RAGE ligand-induced cellular responses. We determined that RAGE ligands activated Gi, but not Gq, only in cells expressing RAGE and wildtype AT1. The activation was inhibited by an AT1 blocker (ARB) as well as a RAGE inhibitor. ARBs inhibited RAGE ligand-induced ERK phosphorylation, NF-κB activation, and epithelial-mesenchymal transition of rat renal epithelial cells. Our findings suggest that the activation of AT1 plays a central role in RAGE-mediated cellular responses and elucidate the role of a novel molecular mechanism in the development of cardiovascular diseases.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33707701      PMCID: PMC7952713          DOI: 10.1038/s41598-021-85312-4

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  26 in total

1.  Functional selectivity profiling of the angiotensin II type 1 receptor using pathway-wide BRET signaling sensors.

Authors:  Yoon Namkung; Christian LeGouill; Sahil Kumar; Yubo Cao; Larissa B Teixeira; Viktoriya Lukasheva; Jenna Giubilaro; Sarah C Simões; Jean-Michel Longpré; Dominic Devost; Terence E Hébert; Graciela Piñeyro; Richard Leduc; Claudio M Costa-Neto; Michel Bouvier; Stéphane A Laporte
Journal:  Sci Signal       Date:  2018-12-04       Impact factor: 8.192

2.  Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis.

Authors:  Raelene J Pickering; Christos Tikellis; Carlos J Rosado; Despina Tsorotes; Alexandra Dimitropoulos; Monique Smith; Olivier Huet; Ruth M Seeber; Rekhati Abhayawardana; Elizabeth Km Johnstone; Jonathan Golledge; Yutang Wang; Karin A Jandeleit-Dahm; Mark E Cooper; Kevin Dg Pfleger; Merlin C Thomas
Journal:  J Clin Invest       Date:  2018-12-10       Impact factor: 14.808

3.  Angiotensin and biased analogs induce structurally distinct active conformations within a GPCR.

Authors:  Laura M Wingler; Meredith A Skiba; Conor McMahon; Dean P Staus; Alissa L W Kleinhenz; Carl-Mikael Suomivuori; Naomi R Latorraca; Ron O Dror; Robert J Lefkowitz; Andrew C Kruse
Journal:  Science       Date:  2020-02-21       Impact factor: 47.728

4.  Angiotensin Analogs with Divergent Bias Stabilize Distinct Receptor Conformations.

Authors:  Laura M Wingler; Matthias Elgeti; Daniel Hilger; Naomi R Latorraca; Michael T Lerch; Dean P Staus; Ron O Dror; Brian K Kobilka; Wayne L Hubbell; Robert J Lefkowitz
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

5.  Dual agonist occupancy of AT1-R-α2C-AR heterodimers results in atypical Gs-PKA signaling.

Authors:  Morgane Bellot; Ségolène Galandrin; Cédric Boularan; Heinrich J Matthies; Fabien Despas; Colette Denis; Jonathan Javitch; Serge Mazères; Samra Joke Sanni; Véronique Pons; Marie-Hélène Seguelas; Jakob L Hansen; Atul Pathak; Aurelio Galli; Jean-Michel Sénard; Céline Galés
Journal:  Nat Chem Biol       Date:  2015-02-23       Impact factor: 15.040

6.  AT1R-CB₁R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II.

Authors:  Raphael Rozenfeld; Achla Gupta; Khatuna Gagnidze; Maribel P Lim; Ivone Gomes; Dinah Lee-Ramos; Natalia Nieto; Lakshmi A Devi
Journal:  EMBO J       Date:  2011-05-03       Impact factor: 11.598

7.  Analysis of Galpha protein recognition profiles of angiotensin II receptors using chimeric Galpha proteins.

Authors:  H Sasamura; M Mifune; H Nakaya; T Amemiya; T Hiraki; I Nishimoto; T Saruta
Journal:  Mol Cell Endocrinol       Date:  2000-12-22       Impact factor: 4.102

8.  Dual inhibition of beta-adrenergic and angiotensin II receptors by a single antagonist: a functional role for receptor-receptor interaction in vivo.

Authors:  Liza Barki-Harrington; Louis M Luttrell; Howard A Rockman
Journal:  Circulation       Date:  2003-09-08       Impact factor: 29.690

9.  The contribution of epithelial-mesenchymal transition to renal fibrosis differs among kidney disease models.

Authors:  Tsutomu Inoue; Akihiro Umezawa; Tsuneo Takenaka; Hiromichi Suzuki; Hirokazu Okada
Journal:  Kidney Int       Date:  2014-07-09       Impact factor: 10.612

10.  Metformin Improves Epithelial-to-Mesenchymal Transition Induced by TGF-β1 in Renal Tubular Epithelial NRK-52E Cells via Inhibiting Egr-1.

Authors:  Meiping Guan; Wenqi Li; Lingling Xu; Yanmei Zeng; Dan Wang; Zongji Zheng; Fuping Lyv; Yaoming Xue
Journal:  J Diabetes Res       Date:  2018-06-27       Impact factor: 4.011

View more
  2 in total

1.  Angiotensin II biphasically regulates cell differentiation in human iPSC-derived kidney organoids.

Authors:  Stacy M Yanofsky; Courtney M Dugas; Akemi Katsurada; Jiao Liu; Zubaida Saifudeen; Samir S El-Dahr; Ryousuke Satou
Journal:  Am J Physiol Renal Physiol       Date:  2021-08-27

Review 2.  RAGE pathway activation and function in chronic kidney disease and COVID-19.

Authors:  Colleen S Curran; Jeffrey B Kopp
Journal:  Front Med (Lausanne)       Date:  2022-08-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.